.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech plan to detail on the Nasdaq under the icon “BIOA,” depending on to files submitted with the Stocks and also Swap Commission. The provider has not publicly discussed an assumed financial quantity for the offering.The clinical-stage provider promotes lead prospect azelaprag, an orally supplied little particle slated to enter phase 2 testing in combo with semaglutide– marketed by Novo Nordisk under trademark name Wegovy for fat burning– in the very first half of following year. Semaglutide is actually additionally offered as Ozempic and also Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is actually created to blend properly with GLP-1 medications, enhancing weight management while keeping muscle mass. The investigational medication was located to be well-tolerated among 265 individuals around 8 phase 1 tests, depending on to BioAge.Earlier, BioAge gathered the support of Lilly to run a test integrating azelaprag along with the Major Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes as Mounjaro and Zepbound for fat loss. The companions are actually presently conducting a stage 2 trial of azelaprag and also tirzepatide, with topline end results assumed in the third quarter of 2025.The biotech is additionally preparing an insulin sensitiveness proof-of-concept test evaluating azelaprag as a monotherapy in the 1st one-half of following year to support prospective indication growth.
On top of that, the firm prepares to talk to the FDA for permission in the second one-half of 2025 to release human testing for an NLRP3 inhibitor targeting metabolic illness and also neuroinflammation.BioAge’s expected transfer to the public market observes a slight uptick in organized biotech IPOs coming from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the current IPO yard is a “mixed photo,” along with high-grade providers still debuting on the public markets, only in lowered amounts, according to PitchBook.